クロロロゲン酸は,HER2/AKT/mTORシグナル伝達経路を調節することにより,グルココルチコイド誘発の骨粗鬆症を軽減する
An-Na Xie1, Sun-Zheng-Yuan Zhang1, Yu Zhang1
1Laboratory of Science and Technology Center, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Journal of integrative medicine
|August 31, 2025
まとめ
クロロロゲン酸 (CGA) は,骨の健康を改善し,骨細胞を標的として,グルココルチコイド誘発性骨粗鬆症 (GIOP) を効果的に治療します. CGAはHER2 / AKT / mTOR経路を調節し,GIOPの潜在的な治療戦略を提供します.
科学分野:
- 生物化学
- 細胞生物学
- 薬理学について
背景:
- グルココルチコイド誘発性骨粗鬆症 (GIOP) は,長期にわたるグルココルチコイド使用による重大な合併症である.
- 伝統的な中国医学のポリフェノールであるクロロゲン酸 (CGA) は,抗酸化特性と潜在的な抗骨症効果を示しています.
研究 の 目的:
- GIOPのマウスモデルでCGAの有効性を調査する.
- GIOPに対するCGAの治療効果の基礎となる分子メカニズムをin vitroとin vivoで探求する.
主な方法:
- CGAの保護効果は,デキサメタゾン誘発のGIOPマウスモデルで,マイクロCT,組織学,および血清分析を用いて評価された.
- 治療目標と経路を予測するためにネットワーク薬理を活用した.
- MLO-Y4細胞におけるメカニズムを検証するために,in vitroアッセイ (染色,フローサイトメトリー,RT-qPCR,ウエスタンブロッティング) を利用した.
主要な成果:
- CGA治療はデキサメタゾンによる骨の喪失を逆転させ,マウスの骨細胞形態を改善した.
- ネットワーク薬理学では,ERBB2 (HER2),カスパース3,および他のタンパク質を主要標的として特定し,ERBB,AKT,およびmTOR経路に関与しています.
- In vitro試験では,CGAが骨の形成を促進し,HER2/ AKT/ mTOR経路の活性化により,MLO- Y4細胞におけるアポトーシスを抑制することを確認した.
結論:
- クロロゲン酸は,GIOPに対する有意な抗骨症効果を示しています.
- CGAは部分的に骨細胞を標的とし,HER2 / AKT / mTORシグナル伝達経路を調節する.
関連する概念動画
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


